147 related articles for article (PubMed ID: 27416091)
1. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
[TBL] [Abstract][Full Text] [Related]
2. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
[TBL] [Abstract][Full Text] [Related]
3. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
5. Erythroderma: An unusual manifestation of imatinib - A rare case report.
Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
[TBL] [Abstract][Full Text] [Related]
6. A case report of rare palmoplantar keratosis and nail dystrophy with imatinib.
Benabbes M; Tazi Mezalek Z; Meddah B
Ann Pharm Fr; 2017 May; 75(3):172-175. PubMed ID: 28189257
[TBL] [Abstract][Full Text] [Related]
7. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.
Huang W; Li J; Qiu F; Wu X; Zhang J; Li X; Yao G; Zhu S
J Clin Pharm Ther; 2020 Aug; 45(4):856-862. PubMed ID: 32479700
[TBL] [Abstract][Full Text] [Related]
9. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
10. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
[TBL] [Abstract][Full Text] [Related]
11. Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
Fujii M; Iwasaki T; Takahashi I; Kishiyama K; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
J Dermatol; 2015 Mar; 42(3):338-9. PubMed ID: 25580575
[No Abstract] [Full Text] [Related]
12. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
Scott AD; Lee M; Kubba F; Chu A
Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
[No Abstract] [Full Text] [Related]
13. Imatinib-induced pseudoporphyria.
Martinez-Mera C; Capusan TM; Herrero-Moyano M; Urquía Renke A; Steegmann Olmedillas JL; de Argila D
Clin Exp Dermatol; 2018 Jun; 43(4):463-466. PubMed ID: 29315788
[No Abstract] [Full Text] [Related]
14. Imatinib mesylate induced erythroderma: A rare case series.
Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
[TBL] [Abstract][Full Text] [Related]
15. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Ramar K; Potti A; Mehdi SA
J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
[No Abstract] [Full Text] [Related]
16. New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
Inayat F; Saif MW
Anticancer Res; 2016 Nov; 36(11):6201-6204. PubMed ID: 27793952
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
[No Abstract] [Full Text] [Related]
18. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
[TBL] [Abstract][Full Text] [Related]
19. Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin.
Teive HAG; Germiniani FMB; Munhoz RP; Camargo CHF
Arq Neuropsiquiatr; 2020 Jan; 78(1):58-59. PubMed ID: 32074181
[No Abstract] [Full Text] [Related]
20. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
[Next] [New Search]